Financial Performance - Net sales for 2025 reached DKK 309,064 million, representing a 6% increase compared to 2024, and a 10% increase at constant exchange rates (CER) [2] - Operating profit decreased by 1% in Danish kroner to DKK 127,658 million, but increased by 6% at CER [2][4] - Net profit for 2025 was DKK 102,434 million, a 1% increase from DKK 100,988 million in 2024 [2] - Diluted earnings per share rose by 2% to DKK 23.03 from DKK 22.63 in 2024 [2] Market and Product Insights - Novo Nordisk achieved a 10% sales growth at CER, reaching nearly 46 million patients with its treatments despite a challenging year [3] - Sales in US Operations increased by 3% in Danish kroner and 8% at CER, while International Operations saw a 10% increase in Danish kroner and 14% at CER [4] - Sales in Obesity and Diabetes care grew by 7% in Danish kroner to DKK 289.5 billion, driven by a 26% increase in Obesity care and a 2% increase in GLP-1 diabetes sales [4] Future Outlook - Adjusted sales growth for 2026 is expected to be between -5% to -13% at CER, influenced by lower realized prices and increased competition [4] - The global GLP-1 market is anticipated to expand, with new treatments like the Wegovy pill expected to enhance patient reach [4] - The company plans to propose a final dividend of DKK 7.95 per share for 2025, totaling DKK 11.70 for the year, and initiate a new share repurchase program of up to DKK 15 billion [4]

Bagsværd, Denmark, 3 February 2026 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit outlook at CER. 2025 sales and operating profit growth at CERIn 2025, Novo Nordisk’s sales increased by 10% and operating profit increased by 6%, compared to previously issued guidance of 8 to 11% sales growth and 4 to 7% operating profit growth1. Sales in US Operations were positively impacted by gross-to-net ...

Pfizer (NYSE: PFE) stock gave up 3.3% through 10:50 a.m. ET Tuesday despite delivering an earnings beat this morning. Analysts forecast the pharmaceuticals giant would earn $0.57 per share on $16.8 billion in Q4 sales. Pfizer actually earned $0.66 (adjusted for one-time items) on sales of $17.6 billion. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » Image source: Getty Images. Pfizer ...

Group 1 - AstraZeneca PLC is recognized for its strong cancer franchise and is recommended to hold by Jim Cramer, who believes it has a better portfolio compared to AbbVie at this moment [1] - AstraZeneca is one of the largest pharmaceutical companies globally, focusing on oncology, cardiovascular, respiratory, and rare diseases, with a robust on-market portfolio and a leading late-stage pipeline [2] - The company is led by CEO Pascal Soriot, noted for his exceptional management and innovative culture, which is expected to drive strong growth in the future [2] Group 2 - Recent regulatory concerns in the United States have overshadowed AstraZeneca's strengths, creating an opportunity for investors to acquire shares below their intrinsic value [2]

Key Takeaways Disney CEO & President Replacements Announced JOLTS Numbers Kick Off "Jobs Week" for FebruaryPYPL, PFE, MRK and MPC Report Q4 Earnings, with Various SuccessAMD, AMGN and CMG Report Q4 Earnings After the CloseTuesday, February 3rd, 2026Kicking off another day of trading, the Dow is flat but other indexes are up: the S&P 500 +0.23%, the Nasdaq +0.51% and the small-cap Russell 2000 +0.32%. The rebound off Friday’s near-term lows continues at a somewhat measured pace, with an apparent bullish sign ...

Fizer and Merc reported earlier today. Join us right now with his reaction to the results is Jeff Meum. He's the head of healthcare research US pharmaceuticals and biotechnology at city.Good morning to you. Uh we've seen both of these stocks. Fizer down by the way 5%.Merc holding in a lot a lot better. But why don't we just go through the headlines here and what your your reaction was. >> Yeah. Yeah.Thanks Andrew for having me. Yeah, I would say for for Merc the guidance was a big worry going into uh the fo ...

Merck & Co., Inc. (NYSE:MRK) on Tuesday reported its fourth-quarter adjusted earnings per share of $2.04, surpassing consensus estimates of $2.01, a jump from $1.72 a year ago.Merck reported sales of $16.40 billion, a 5% increase year-over-year, and exceeded the analysts' projections of $16.19 billion.Segment And Drug PerformanceThe pharmaceutical segment recorded $14.84 billion in sales, up 6% year over year, driven by growth in oncology as well as cardiometabolic and respiratory, partially offset by a dec ...

Company Performance - Pfizer Inc (NYSE:PFE) shares decreased by 3.2%, trading at $25.40, despite exceeding earnings and revenue expectations for Q4 [1] - The company is facing weak demand for its Covid-19 vaccine and has reaffirmed a lackluster outlook for 2026 [1] - Merck & Co Inc (NYSE:MRK) reported profits of $2.04 per share on sales of $16.4 billion, surpassing analysts' estimates for Q4, with shares up 2.5% to $116.19 [3] Market Trends - Pfizer's stock is experiencing overhead pressure near the $27 level, limiting gains since November, and is on track to end a three-day winning streak with its worst loss since December [2] - Merck is on track to achieve its fourth consecutive win, having surged to its highest level since September, with a notable 46.8% nine-month lead [3] Options Activity - Put volume for Pfizer is running at double the intraday average, with the February 24 put being the most popular option [4] - Merck is also seeing double the overall options volume typically observed, with the 110 call in the same series leading the way [4]

Financial Data and Key Metrics Changes - For the full year 2025, the company recorded revenues of $62.6 billion, a 2% operational decline from $63.6 billion in the previous year. Excluding COVID-19 products, operational revenue growth was 6% [28] - Adjusted gross margins for the full year expanded to 76%, aligning with expectations. The diluted EPS for 2025 was $1.36, down from $1.41 the previous year, while adjusted diluted EPS increased to $3.22 from $3.11 [28][32] - In Q4 2025, revenues were $17.6 billion, a 3% operational decline year-over-year, primarily due to a 40% decline in COVID product sales. Non-COVID product performance grew 9% operationally [29][30] Business Line Data and Key Metrics Changes - Recently launched and acquired products generated $10.2 billion in revenues for 2025, growing approximately 14% operationally compared to the previous year [29] - The decline in COVID product sales was attributed to reduced demand for Comirnaty and Paxlovid due to lower infection rates [29][30] Market Data and Key Metrics Changes - The company anticipates stable revenue contributions from its non-COVID product portfolio, with an expected revenue compression of approximately $1.5 billion due to generic entry in 2026 [36] - The market for obesity treatments is projected to be $150 billion, with significant opportunities for the company's new obesity pipeline [10][48] Company Strategy and Development Direction - The company aims for industry-leading growth as key products lose patent or regulatory exclusivity in the coming years, focusing on maximizing the value of in-line product portfolios and accelerating pipeline development [7][12] - Strategic acquisitions, including Seagen, Metsera, and Biohaven, are expected to drive future growth [7][12] - The company is investing in artificial intelligence across various functions to enhance productivity and innovation [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate uncertainties and deliver on financial commitments, despite challenges from the COVID-19 product decline [5][6] - The company is focused on investing in key assets and managing upcoming loss of exclusivity (LOE) challenges, with growth expected from its advancing R&D pipeline and business development initiatives [36][38] Other Important Information - The company achieved approximately $600 million in savings from its manufacturing optimization program in 2025, with additional savings expected in the following years [30][33] - The company plans to advance over 20 obesity trials in 2026, including 10 Phase III studies [22] Q&A Session Questions and Answers Question: Can you elaborate on the tolerability seen in the VESPER-3 data? - Management indicated that the tolerability data will be shared at the ADA conference, noting that the distribution of adverse events was encouraging and did not show significant increases in discontinuation rates [41][42] Question: What role do you see for the drug with the current weight loss profile in the market? - Management believes that the drug's efficacy combined with a lower medication burden through monthly dosing will resonate well with patients and providers, enhancing its commercial potential [46] Question: Did the placebo arm in the VESPER-3 study gain or lose weight? - The placebo arm remained stable, showing no significant weight gain or loss, with full data to be presented at ADA [61] Question: What are the plans for the Phase III studies regarding down titration? - The Phase III design will allow for flexibility in dosing and titration to improve overall efficacy and tolerability [52][53] Question: What is the company's strategy regarding portfolio realignment? - The company has completed most of its pipeline pruning and is focusing on high-value programs, with significant savings reinvested into Phase III programs [84][86]

Financial Data and Key Metrics Changes - For the full year 2025, the company recorded revenues of $62.6 billion, a 2% operational decline from $63.6 billion in the previous year. Excluding COVID-19 products, operational revenue growth was 6% [29] - Adjusted gross margins for the full year expanded to 76%, aligning with expectations, while diluted EPS was reported at $1.36 compared to $1.41 last year, and adjusted diluted EPS increased to $3.22 from $3.11 [29][30] - In Q4 2025, revenues were $17.6 billion, a 3% operational decline year-over-year, primarily due to a 40% decline in COVID product sales. Non-COVID product performance grew 9% operationally [30][31] Business Line Data and Key Metrics Changes - Recently launched and acquired products generated $10.2 billion in revenues for 2025, growing approximately 14% operationally [30] - The decline in COVID product sales was attributed to reduced demand for COMIRNATY and PAXLOVID due to lower infection rates [30] Market Data and Key Metrics Changes - The company anticipates stable revenue contributions from its non-COVID product portfolio, with an expected revenue compression of approximately $1.5 billion due to anticipated generic entry in 2026 [39] - The market for obesity treatments, particularly for the ultra-long-acting GLP-1 receptor agonist, is projected to be $150 billion, with significant opportunities in both mature and emerging markets [51] Company Strategy and Development Direction - The company aims for industry-leading growth as key products lose patent or regulatory exclusivity in the coming years, focusing on maximizing the value of in-line product portfolios and accelerating pipeline development [7][12] - Strategic acquisitions, including Seagen, Metsera, and Biohaven, are seen as transformative for the company, with a commitment to invest in R&D and maintain a robust dividend [7][12][37] - The company is scaling artificial intelligence across various functions to improve productivity and accelerate innovation [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong financial performance despite challenges, highlighting the resilience of the business and the successful execution of strategic priorities [5][27] - The company expects to face headwinds from loss of exclusivity (LOE) for several products but remains focused on investing in key assets to drive growth by the end of the decade [39][40] Other Important Information - The company achieved significant cost savings through manufacturing optimization programs, with expectations of additional savings in the coming years [31][34] - The company plans to advance over 20 pivotal studies in 2026, targeting potential approvals starting in 2028 for its obesity portfolio [23][25] Q&A Session Summary Question: Can you elaborate on the tolerability seen in VESPER-3 data? - Management indicated that the tolerability data will be shared at ADA, noting that the distribution of adverse events was encouraging, with no significant increase in discontinuations when switching to monthly dosing [43][45] Question: What role do you see for the drug with solid weight loss but potentially below competitors? - Management believes that the combination of competitive efficacy and a lower medication burden through monthly dosing will resonate well with patients and providers, enhancing the drug's market potential [49] Question: Did the placebo arm gain or lose weight in VESPER-3? - The placebo arm remained stable, showing no significant weight gain or loss, with detailed data to be presented at ADA [65] Question: What are the expectations for the upcoming phase III studies? - Management expressed confidence in the ongoing studies, highlighting the promising data observed so far and the potential for differentiation in the market [84][90]